[1]常瑞霞,可春梅.血小板相关参数和凝血指标在肺癌治疗中的变化及意义[J].陕西医学杂志,2021,50(5):610-613.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
　CHANG Ruixia,KE Chunmei.Changes and significance of platelet-related parameters and coagulation indexes in treatment of lung cancer[J].,2021,50(5):610-613.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
点击复制

血小板相关参数和凝血指标在肺癌治疗中的变化及意义
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年5期
页码:
610-613
栏目:
临床检验
出版日期:
2021-05-05

文章信息/Info

Title:
Changes and significance of platelet-related parameters and coagulation indexes in treatment of lung cancer
作者:
常瑞霞; 可春梅
(郑州市第六人民医院,河南 郑州 450000)
Author(s):
CHANG Ruixia; KE Chunmei
(The Sixth People's Hospital of Zhengzhou,Zhengzhou 450000,China)
关键词:
肺癌;  血小板相关参数;  凝血指标;  化疗;  监测
Keywords:
Lung cancer;  Platelet-related parameters;  Coagulation indexes;  Chemotherapy;  Monitoring
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2021.05.024
文献标志码:
A
摘要:
目的:分析血小板相关参数和凝血指标在肺癌治疗中的变化及意义。方法:选择75例肺癌患者作为观察组,另选同期接受健康体检的75例健康者作为对照组。观察组接受顺铂+吉西他滨(GP方案)化疗。对比两组患者化疗前后血小板相关参数[血小板压积(PCT)、血小板计数(PLT)、血小板分布宽度(PDW)、平均血小板体积(MPV)]和凝血指标[凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、D-二聚体(D-D)]。结果:观察组治疗前PCT、PLT、MPV比对照组高,治疗后比治疗前降低(均P<0.05)。观察组治疗前TT、PT、APTT与对照组相比,差异无统计学意义(均P>0.05); 观察组治疗前FIB、D-D比对照组高,治疗后TT、PT、APTT、FIB、D-D均比治疗前低(均P<0.05)。治疗前,Ⅲ-Ⅳ期患者PT、TT显著高于Ⅰ-Ⅱ期,APTT、PLT、PCT、PDW、MPV和D-D显著低于Ⅰ-Ⅱ期(均P<0.05)。治疗后,TNM各分期患者凝血指标、血小板相关参数均较治疗前同TNM分期患者下降显著,且Ⅲ-Ⅳ期患者D-D、PDW低于Ⅰ-Ⅱ期,TT、PCT、PLT高于Ⅰ-Ⅱ期(均P<0.05)。结论:肺癌患者处于血液高凝、血小板活化等病理状态,化疗会进一步加剧凝血功能紊乱,故化疗期间密切监测上述指标变化具有重要意义。
Abstract:
Objective:To analyze the changes and significance of platelet-related parameters and coagulation indexes in the treatment of lung cancer.Methods:75 patients with lung cancer were selected as observation group,and 75 healthy people with physical examination were taken as control group.The observation group received cisplatin+gemcitabine(GP regimen)chemotherapy.The platelet-related parameters [thrombocytocrit(PCT),blood platelet count(PLT),platelet distribution width(PDW),mean platelet volume(MPV)] and coagulation indexes [thrombin time(TT),prothrombin time(PT),activated partial thromboplastin time(APTT),fibrinogen(FIB),D-dimer(D-D)] in the two groups before and after chemotherapy were compared.Results:The PCT,PLT,and MPV of the observation group before treatment were higher than those of the control group,and they were lower after treatment than before treatment(all P<0.05).Compared with the control group,the TT,PT,APTT of the observation group before treatment were not statistically different(all P>0.05); the FIB and DD of the observation group before treatment were higher than those of the control group,and the TT,PT,APTT,FIB,DD after treatment All were lower than before treatment(all P<0.05).Before treatment,the PT and TT of stage Ⅲ-Ⅳ patients were significantly higher than those of stage Ⅰ-Ⅱ,and APTT,PLT,PCT,PDW,MPV and D-D were significantly lower than those of stage Ⅰ-Ⅱ(all P<0.05).After treatment,the coagulation indexes and platelet-related parameters of patients in each TNM stage were significantly lower than those in the same TNM stage before treatment,and the DD and PDW of patients in stage Ⅲ-Ⅳ were lower than those in stage Ⅰ-Ⅱ,and TT,PCT and PLT were higher than those in stageⅠ-Ⅱ(all P<0.05).Conclusion:Patients with lung cancer are in pathological conditions such as blood hypercoagulability and platelet activation.Chemotherapy will further aggravate the coagulation disorder.Therefore,it is important to monitor the changes of the above indicators during chemotherapy.

参考文献/References:

[1] 王丽杰,张初峰,王 鹏,等.局限期小细胞肺癌交替与序贯放化疗对照研究[J].中华肿瘤防治杂志,2015,22(4):289-292.
[2] 邵翠丽,周晋华,杨勤军,等.周晋华运用环磷酰胺联合中药紫杉治疗晚期肺癌经验[J].陕西中医,2020,41(2):223-225.
[3] 宋国强,陈 飞,陈墩顺,等.非小细胞肺癌患者凝血功能及血小板异常的相关因素分析[J].浙江医学,2018,40(4):361-364.
[4] Mongeon M,Thibault F,Chartrandlefebvre C,et al.Safety and efficacy of endovascular fiducial marker insertion for cyberknife stereotactic radiation therapy planning in early-stage lung cancer[J].Journal of Vascular & Interventional Radiology,2017,28(8):1090-1097.
[5] 中华人民共和国卫生部.中国常见恶性肿瘤诊治规范[M].北京:北京医科大学、中国协和医科大学联合出版社,1991:1-2.
[6] 卢 滨,吴红科,姚菲菲,等.吉西他滨与培美曲塞联合顺铂治疗非小细胞肺癌的疗效比较及对血清肿瘤标志物的影响[J].实用癌症杂志,2017,32(6):975-977.
[7] 董 蕙,王存德,龚 泉,等.凝血因子Ⅲ在非小细胞肺癌高凝状态患者外周血中的表达及其临床意义[J].中国肿瘤临床,2018,45(8):385-389.
[8] 马宇辰,张 华,张 彬,等.术前血小板及血浆纤维蛋白原对早期非小细胞肺癌的预后价值[J].中国肿瘤临床,2018,45(5):222-227.
[9] Cho EN,Park HS,Kim TH,et al.A rare case of primary thymic adenocarcinoma mimicking small cell lung cancer[J].Tuberculosis & Respiratory Diseases,2015,78(2):112-119.
[10] 崔建国,刘传河.DCCIK联合GC方案治疗晚期非小细胞肺癌合并血栓患者的临床疗效以及对凝血指标的影响[J].血栓与止血学,2018,24(4):608-609,612.
[11] 张 波,姚月娟,苏鹏程,等.晚期非小细胞肺癌患者血浆凝血指标与预后的关系[J].中国医师杂志,2018,20(8):1225-1227.
[12] Brosseau S,Gounant V,Naltet C,et al.Lazarus syndrome with crizotinib in a non-small-cell lung cancer patient with ROS1 rearrangement and disseminated intravascular coagulation[J].Clinical Lung Cancer,2018,19(1):57-61.
[13] 付 阳,刘玉梅,金亚雄,等.凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究[J].中国肺癌杂志,2018,21(8):583-587.
[14] 杨桂学,吴 卓,张 磊,等.肺癌患者血清肿瘤标志物与凝血功能变化相关性研究[J].现代肿瘤医学,2018,26(16):2519-2523.
[15] Yang X,Zhang H,Kong F,et al.Effect of huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer[J].Journal of Thoracic Disease,2017,9(7):1891-1902.
[16] 耿 平,李爱君,张雪伟,等.血液高凝肺癌患者应用低分子肝素后凝血功能的变化情况[J].现代肿瘤医学,2018,26(2):212-215.
[17] 李君艳,陈国荣.肺癌患者凝血指标与临床特征的关系[J].陕西医学杂志,2019,48(6):718-721.
[18] 刘海涛,衣秀秀,田建辉.肺癌中西医抗凝治疗研究进展[J].陕西中医,2020,41(1):127-130.
[19] 刘 健,孙增涛,刘 伟,等.益气活血解毒法对肺癌微环境作用探析[J].陕西中医,2018,39(9):1285-1287.
[20] 何 静,郭 玲,单锦露.肺癌患者血液流变学及相关指标变化的临床分析[J].中国临床医生杂志,2021,49(1):35-37.
[21] 苏振华,章怀成,江 强.肺癌患者血小板参数与其临床病理特征相关性分析[J].检验医学,2020,35(5):461-463.

相似文献/References:

[1]贾丽娟,杜苏丰.重组新城疫病毒疫苗rlRVG对A549荷瘤小鼠瘤体生长的抑制作用[J].陕西医学杂志,2019,(1):6.
　JIA Lijuan,DU Sufeng..The tumor growth influence of recombinant NDV (rlRVG) on lung adenocarcinoma A549transfected in vivo[J].,2019,(5):6.
[2]江茂琼,贾钰铭△,叶文静,等.MDSCs对肺癌小鼠CD8+T细胞及生存期的影响研究[J].陕西医学杂志,2019,(3):293.
　JIANG Maoqiong,JIA Yuming,LI Ting,et al.Effect of MDSCs on CD8 T cells and survival time of lung cancer mice[J].,2019,(5):293.
[3]李君艳,陈国荣.肺癌患者凝血指标与临床特征的关系*[J].陕西医学杂志,2019,(6):718.
　LI Junyan,CHEN Guorong..The relationships between coagulation indicators and clinic characterisitics of patients with lung cancer[J].,2019,(5):718.
[4]王 玲,申 鸿.癌胚抗原、糖类抗原、CA125、血管生成素、细胞角蛋白19片段及甲胎蛋白检测在肺癌诊断中的临床研究*[J].陕西医学杂志,2019,(8):1080.
　WANG Ling,SHEN Hong..The value of tumor markers CEA，CA199，CA125，Ang-2，CYFRA211 and AFP in the diagnosis of lung cancer[J].,2019,(5):1080.
[5]韩 乐,陈文娟△,雷光焰,等.microRNA21、microRNA25在肺癌组织中的表达及意义*[J].陕西医学杂志,2019,(12):1596.
　HAN Le,CHEN Wenjuan,LEI Guangyan,et al.Expression and significance of microRNA21 and microRNA25 in lung cancer tissues[J].,2019,(5):1596.
[6]王 勇,张 勇,白正忠△.单操作孔完全胸腔镜与传统三孔胸腔镜治疗老年肺癌疗效对比研究*[J].陕西医学杂志,2019,(12):1670.
[7]米卫国.负压引流管在单操作孔胸腔镜下肺癌根治术中的临床应用研究[J].陕西医学杂志,2021,50(7):839.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.018]
　MI Weiguo.Application effect of negative pressure drainage tube in patients undergoing radical surgery for lung cancer under single-port thoracoscopy[J].,2021,50(5):839.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.018]
[8]张玉琨,李 波,刘 静,等.迷走神经保护对胸腔镜下肺癌根治术后房颤发生的预防作用[J].陕西医学杂志,2021,50(10):1267.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.023]
[9]米 婷,王雅宁.气管镜下宏基因组学二代测序技术在肺癌鉴别诊断中的临床应用价值[J].陕西医学杂志,2022,51(4):437.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.012]
[10]张军艳,谷 俊.程序性死亡配体1在肺癌组织中的表达及其与患者病理特征和疾病预后相关性研究[J].陕西医学杂志,2022,51(7):894.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.031]
　ZHANG Junyan,GU Jun.Expression of programmed death ligand 1 in lung cancer tissues and its correlation with pathological characteristics and prognosis[J].,2022,51(5):894.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.031]

备注/Memo

备注/Memo:
基金项目:河南省医学科技攻关计划项目(2018020848)
更新日期/Last Update: 2021-05-06